A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: ER+ HER2- Advanced Breast Cancer|High-grade Serous Ovarian Cancer (HGSOC)
Interventions: DRUG: AZD8421|DRUG: Camizestrant|DRUG: Ribociclib|DRUG: Palbociclib|DRUG: Abemaciclib
Sponsor: AstraZeneca